Bank of America Securities Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $145.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ahmad has an average return of 2.6% and a 52.93% success rate on recommended stocks.
In addition to Bank of America Securities, Rhythm Pharmaceuticals also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on January 20. However, on January 16, TipRanks – xAI reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).
Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $51.3 million and a GAAP net loss of $52.9 million. In comparison, last year the company earned a revenue of $33.25 million and had a GAAP net loss of $43.64 million
Read More on RYTM:
Disclaimer & DisclosureReport an Issue
- Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
- Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
- Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue
